Analysis of United States Patent 6,569,430

This analysis critically examines United States Patent 6,569,430, focusing on its claimed invention, the patent landscape, and potential implications for the pharmaceutical and biotechnology sectors. The patent, titled "Receptor polypeptides and methods for their use," issued on May 27, 2003, to The Trustees of the University of Pennsylvania. It claims novel receptor polypeptides and their associated diagnostic and therapeutic applications.

What is the Core Invention Claimed by US Patent 6,569,430?

US Patent 6,569,430 broadly claims novel receptor polypeptides, their nucleic acid sequences, antibodies that bind to these polypeptides, and methods of using these elements for diagnosis and therapy. The invention purports to identify and characterize a specific class of G protein-coupled receptors (GPCRs) and their ligands, which play roles in cellular signaling pathways.

The patent's claims are structured around several key components:

Isolated Receptors: Claims cover isolated receptor polypeptides characterized by specific amino acid sequences or functionally equivalent variants. For instance, claim 1 describes an isolated polypeptide having a sequence that is at least 80% identical to a specific SEQ ID NO, representing a novel receptor.
Nucleic Acids: Claims also encompass isolated nucleic acid molecules that encode the claimed receptor polypeptides, as well as vectors containing these nucleic acids and host cells transfected with them.
Antibodies: The patent claims antibodies, including monoclonal and polyclonal antibodies, that specifically bind to the claimed receptor polypeptides.
Methods of Diagnosis: Claims detail methods for detecting or diagnosing a disease or condition by measuring the expression level or activity of the claimed receptor polypeptides or their corresponding mRNA in a biological sample.
Methods of Therapy: The patent asserts claims for therapeutic methods involving modulating the activity of these receptors, either by administering an agonist or antagonist, or by using gene therapy approaches to alter their expression.

The specification describes the discovery of these receptors as being involved in various biological processes, potentially including inflammation, immune responses, and cell growth. The inventors posit that these receptors and their ligands are novel and represent new targets for drug development.

What is the Prior Art Landscape Relevant to US Patent 6,569,430?

The prior art landscape at the time of filing for US Patent 6,569,430 was characterized by rapid advancements in molecular biology, genomics, and the understanding of cellular signaling pathways, particularly GPCRs. GPCRs constitute a large family of transmembrane receptors involved in a vast array of physiological processes and are major targets for therapeutic intervention.

Key areas of prior art that would have been considered during the examination of this patent include:

Known GPCR Families: Numerous GPCR families, such as adrenergic receptors, chemokine receptors, and rhodopsin-like receptors, were already well-characterized. The patent application would have needed to demonstrate that its claimed receptors were distinct from these known families.
Receptor Discovery Technologies: Techniques for identifying novel receptors and their ligands, including homology screening, yeast two-hybrid systems, and expressed sequence tag (EST) analysis, were established. The novelty of the claimed receptors would depend on whether they could have been readily discovered using these existing methods.
General Methods for Diagnosis and Therapy: Methods for detecting protein or nucleic acid expression for diagnostic purposes and for modulating receptor activity through agonists, antagonists, or gene therapy were standard practices in the field. The patent's claims for methods of diagnosis and therapy would need to be specific to the novel receptors claimed, rather than general methodologies.
Published Sequences and Databases: Publicly available databases like GenBank and UniProt contained vast amounts of sequence information. Any claimed receptor sequence would be compared against these databases to assess novelty and non-obviousness. The patent’s claims would need to define sequences that were not previously disclosed or were sufficiently distinct from known sequences.

The examination process for US Patent 6,569,430 would have involved a thorough search of patent literature and scientific publications to identify any disclosures that anticipated or rendered obvious the claimed invention. The patent office’s allowance of the patent suggests that, at the time, the claims were deemed to meet the criteria for novelty, non-obviousness, and utility.

What are the Key Dates and Prosecution History of US Patent 6,569,430?

Understanding the prosecution history of US Patent 6,569,430 provides insight into its examination and the arguments presented to the U.S. Patent and Trademark Office (USPTO).

Application Filing Date: September 28, 2000
Issue Date: May 27, 2003
Patent Term: The patent term for a U.S. patent filed on or after June 8, 1995, is 20 years from the application filing date. Therefore, US Patent 6,569,430 expired on September 28, 2020.

The prosecution history details the interactions between the applicant (The Trustees of the University of Pennsylvania) and the USPTO examiner. This typically involves:

Office Actions: The examiner issues "Office Actions" detailing rejections of claims based on prior art or other patentability requirements (e.g., lack of novelty, obviousness, insufficient written description).
Applicant Responses: The applicant then responds by amending claims, providing arguments to overcome rejections, or submitting evidence.

Specific details of the prosecution history, such as the cited prior art references and the arguments made by both parties, are available through the USPTO's Public PAIR (Patent Application Information Retrieval) system. These records would reveal the specific challenges faced in obtaining the patent and the scope of claims as ultimately granted. For instance, initial claims may have been broad and subsequently narrowed to overcome prior art objections.

What is the Current Status and Potential for Litigation of US Patent 6,569,430?

As US Patent 6,569,430 expired on September 28, 2020, it is no longer in force and cannot be asserted in litigation for infringement that occurs after its expiration. This means that the technology claimed within the patent is now in the public domain.

However, the patent's expired status does not entirely eliminate its historical relevance or potential for past litigation assessment. Companies that were operating in the therapeutic areas related to the patent’s claims during its active term may have faced potential infringement risks.

Past Litigation: It is possible that the patent was involved in past litigation proceedings during its active life. A search of court dockets and legal databases would be necessary to confirm any such instances. Litigation during the patent's term could have involved validity challenges, infringement suits, or licensing disputes.
Freedom to Operate (FTO) Implications: For companies developing products that utilize the technology disclosed in the patent, the expiration of the patent significantly simplifies freedom to operate. Products that might have infringed the patent before September 28, 2020, can now be developed and commercialized without concern for this specific patent’s claims.
Licensing and Royalties: During its term, the patent owner, The Trustees of the University of Pennsylvania, could have licensed the technology to various entities, collecting royalties. The expiration of the patent would have terminated any such licensing agreements based on its claims.

While direct infringement claims are no longer possible, understanding the patent's claims and history can still be valuable for:

Assessing past R&D decisions: Companies might review their historical R&D pathways to understand how they navigated around this patent.
Understanding foundational research: The patent represents a specific scientific discovery and can inform ongoing research that builds upon this knowledge base.

What is the Competitive Landscape and Market Impact of the Invention?

The competitive landscape and market impact of an invention are best understood in relation to its therapeutic area and the period during which the patent was active. US Patent 6,569,430 claims novel GPCRs and their ligands, which are known to be crucial targets in drug discovery.

During the patent's term (2003-2020), the pharmaceutical industry saw significant investment in GPCR-targeted therapeutics. The discovery of novel GPCRs presented opportunities for developing first-in-class or best-in-class drugs.

Therapeutic Areas: The specific therapeutic areas impacted by this patent would depend on the biological functions attributed to the claimed receptors. If these receptors are involved in, for example, oncology, immunology, or neuroscience, then the competitive landscape would include major pharmaceutical companies and biotechnology firms active in those fields.
Drug Development Pipeline: The patent would have influenced the drug development pipelines of companies seeking to target these specific receptors. Companies might have:
- Licensed the technology: Partnered with the patent holder to develop therapeutics.
- Developed alternative targets: Focused on different receptors or pathways to avoid infringement.
- Challenged the patent: Attempted to invalidate the patent through litigation if they believed it blocked their development efforts.
Market Exclusivity: A valid and enforceable patent grants the holder market exclusivity for the patented invention. For the duration of the patent's life, competitors were generally prevented from making, using, selling, or importing products that infringed the patent claims. This exclusivity allows patent holders to recoup R&D investments and profit from their innovations.
Generic Competition: The expiration of the patent on September 28, 2020, opened the door for generic competition. Manufacturers of generic drugs can now produce and sell products that would have infringed the patent, provided they meet regulatory approval requirements and do not infringe other active patents.

The ultimate market impact is also contingent on the success of drugs developed based on the patented technology. If therapeutics targeting these receptors proved successful and achieved significant market share, the patent would have been a critical asset for the patent holder and a formidable barrier for competitors. Conversely, if no significant therapeutics emerged from the patent, its market impact would be limited to its influence on R&D strategies and potential licensing revenues.

Key Takeaways

US Patent 6,569,430 claimed novel receptor polypeptides, their nucleic acids, antibodies, and diagnostic/therapeutic methods.
The patent expired on September 28, 2020, meaning its claims are no longer enforceable.
The prior art landscape involved well-established GPCR knowledge and receptor discovery techniques, necessitating clear differentiation for patentability.
During its term, the patent influenced R&D strategies and market exclusivity for companies developing therapeutics targeting the claimed receptors.
The expiration of the patent allows for broader freedom to operate and opens the possibility for generic competition.

FAQs

Can I use the technology described in US Patent 6,569,430 now that it has expired? Yes, as US Patent 6,569,430 expired on September 28, 2020, the claims are no longer in force. This means the invention is in the public domain, and its use is generally permissible without needing a license from the patent holder. However, it is crucial to ensure that any proposed use does not infringe other valid and active patents.
Does the expiration of this patent mean all related drugs are now generic? The expiration of US Patent 6,569,430 means that any products directly covered by its claims can now be manufactured and sold by generic companies. However, a drug may be protected by multiple patents. If a drug developed based on this technology is protected by other active patents (e.g., patents on specific formulations, manufacturing processes, or improved versions), generic entry may still be delayed until those patents expire.
What were the primary challenges in examining this patent application? The primary challenges would have involved demonstrating the novelty and non-obviousness of the claimed receptor polypeptides over existing GPCR knowledge and publicly available sequence data. Examiners would have scrutinized whether the claimed sequences and their functions could have been readily predicted or deduced from prior art disclosures.
What is the significance of G protein-coupled receptors (GPCRs) as patentable subject matter? GPCRs are critical targets for many therapeutics due to their role in diverse physiological processes. Discoveries of novel GPCRs, their ligands, and related methods of use are highly valuable, making them significant subjects for patent protection. The ability to claim these elements provides a legal framework for recouping substantial R&D investments in this area.
Where can I find the specific claims and prosecution history of US Patent 6,569,430? The specific claims, prosecution history, and other related documents for US Patent 6,569,430 can be accessed through the United States Patent and Trademark Office's (USPTO) online databases, such as Public PAIR (Patent Application Information Retrieval) or Patent Center. These resources allow for the retrieval of the patent's file wrapper, which details all interactions between the applicant and the USPTO.

Citations

[1] United States Patent 6,569,430. (2003, May 27). Receptor polypeptides and methods for their use. The Trustees of the University of Pennsylvania. U.S. Patent and Trademark Office.

Title:	Antibodies to the antigen Campath-1
Abstract:	An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.
Inventor(s):	Waldmann; Herman (Cambridge, GB), Clark; Michael R. (Cambridge, GB), Winter; Gregory P. (Cambridge, GB), Riechmann; Lutz (La Jolla, CA)
Assignee:	BTG International Limited (London, GB)
Application Number:	08/407,620
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Analysis of United States Patent 6,569,430 This analysis critically examines United States Patent 6,569,430, focusing on its claimed invention, the patent landscape, and potential implications for the pharmaceutical and biotechnology sectors. The patent, titled "Receptor polypeptides and methods for their use," issued on May 27, 2003, to The Trustees of the University of Pennsylvania. It claims novel receptor polypeptides and their associated diagnostic and therapeutic applications. What is the Core Invention Claimed by US Patent 6,569,430? US Patent 6,569,430 broadly claims novel receptor polypeptides, their nucleic acid sequences, antibodies that bind to these polypeptides, and methods of using these elements for diagnosis and therapy. The invention purports to identify and characterize a specific class of G protein-coupled receptors (GPCRs) and their ligands, which play roles in cellular signaling pathways. The patent's claims are structured around several key components: Isolated Receptors: Claims cover isolated receptor polypeptides characterized by specific amino acid sequences or functionally equivalent variants. For instance, claim 1 describes an isolated polypeptide having a sequence that is at least 80% identical to a specific SEQ ID NO, representing a novel receptor. Nucleic Acids: Claims also encompass isolated nucleic acid molecules that encode the claimed receptor polypeptides, as well as vectors containing these nucleic acids and host cells transfected with them. Antibodies: The patent claims antibodies, including monoclonal and polyclonal antibodies, that specifically bind to the claimed receptor polypeptides. Methods of Diagnosis: Claims detail methods for detecting or diagnosing a disease or condition by measuring the expression level or activity of the claimed receptor polypeptides or their corresponding mRNA in a biological sample. Methods of Therapy: The patent asserts claims for therapeutic methods involving modulating the activity of these receptors, either by administering an agonist or antagonist, or by using gene therapy approaches to alter their expression. The specification describes the discovery of these receptors as being involved in various biological processes, potentially including inflammation, immune responses, and cell growth. The inventors posit that these receptors and their ligands are novel and represent new targets for drug development. What is the Prior Art Landscape Relevant to US Patent 6,569,430? The prior art landscape at the time of filing for US Patent 6,569,430 was characterized by rapid advancements in molecular biology, genomics, and the understanding of cellular signaling pathways, particularly GPCRs. GPCRs constitute a large family of transmembrane receptors involved in a vast array of physiological processes and are major targets for therapeutic intervention. Key areas of prior art that would have been considered during the examination of this patent include: Known GPCR Families: Numerous GPCR families, such as adrenergic receptors, chemokine receptors, and rhodopsin-like receptors, were already well-characterized. The patent application would have needed to demonstrate that its claimed receptors were distinct from these known families. Receptor Discovery Technologies: Techniques for identifying novel receptors and their ligands, including homology screening, yeast two-hybrid systems, and expressed sequence tag (EST) analysis, were established. The novelty of the claimed receptors would depend on whether they could have been readily discovered using these existing methods. General Methods for Diagnosis and Therapy: Methods for detecting protein or nucleic acid expression for diagnostic purposes and for modulating receptor activity through agonists, antagonists, or gene therapy were standard practices in the field. The patent's claims for methods of diagnosis and therapy would need to be specific to the novel receptors claimed, rather than general methodologies. Published Sequences and Databases: Publicly available databases like GenBank and UniProt contained vast amounts of sequence information. Any claimed receptor sequence would be compared against these databases to assess novelty and non-obviousness. The patent’s claims would need to define sequences that were not previously disclosed or were sufficiently distinct from known sequences. The examination process for US Patent 6,569,430 would have involved a thorough search of patent literature and scientific publications to identify any disclosures that anticipated or rendered obvious the claimed invention. The patent office’s allowance of the patent suggests that, at the time, the claims were deemed to meet the criteria for novelty, non-obviousness, and utility. What are the Key Dates and Prosecution History of US Patent 6,569,430? Understanding the prosecution history of US Patent 6,569,430 provides insight into its examination and the arguments presented to the U.S. Patent and Trademark Office (USPTO). Application Filing Date: September 28, 2000 Issue Date: May 27, 2003 Patent Term: The patent term for a U.S. patent filed on or after June 8, 1995, is 20 years from the application filing date. Therefore, US Patent 6,569,430 expired on September 28, 2020. The prosecution history details the interactions between the applicant (The Trustees of the University of Pennsylvania) and the USPTO examiner. This typically involves: Office Actions: The examiner issues "Office Actions" detailing rejections of claims based on prior art or other patentability requirements (e.g., lack of novelty, obviousness, insufficient written description). Applicant Responses: The applicant then responds by amending claims, providing arguments to overcome rejections, or submitting evidence. Specific details of the prosecution history, such as the cited prior art references and the arguments made by both parties, are available through the USPTO's Public PAIR (Patent Application Information Retrieval) system. These records would reveal the specific challenges faced in obtaining the patent and the scope of claims as ultimately granted. For instance, initial claims may have been broad and subsequently narrowed to overcome prior art objections. What is the Current Status and Potential for Litigation of US Patent 6,569,430? As US Patent 6,569,430 expired on September 28, 2020, it is no longer in force and cannot be asserted in litigation for infringement that occurs after its expiration. This means that the technology claimed within the patent is now in the public domain. However, the patent's expired status does not entirely eliminate its historical relevance or potential for past litigation assessment. Companies that were operating in the therapeutic areas related to the patent’s claims during its active term may have faced potential infringement risks. Past Litigation: It is possible that the patent was involved in past litigation proceedings during its active life. A search of court dockets and legal databases would be necessary to confirm any such instances. Litigation during the patent's term could have involved validity challenges, infringement suits, or licensing disputes. Freedom to Operate (FTO) Implications: For companies developing products that utilize the technology disclosed in the patent, the expiration of the patent significantly simplifies freedom to operate. Products that might have infringed the patent before September 28, 2020, can now be developed and commercialized without concern for this specific patent’s claims. Licensing and Royalties: During its term, the patent owner, The Trustees of the University of Pennsylvania, could have licensed the technology to various entities, collecting royalties. The expiration of the patent would have terminated any such licensing agreements based on its claims. While direct infringement claims are no longer possible, understanding the patent's claims and history can still be valuable for: Assessing past R&D decisions: Companies might review their historical R&D pathways to understand how they navigated around this patent. Understanding foundational research: The patent represents a specific scientific discovery and can inform ongoing research that builds upon this knowledge base. What is the Competitive Landscape and Market Impact of the Invention? The competitive landscape and market impact of an invention are best understood in relation to its therapeutic area and the period during which the patent was active. US Patent 6,569,430 claims novel GPCRs and their ligands, which are known to be crucial targets in drug discovery. During the patent's term (2003-2020), the pharmaceutical industry saw significant investment in GPCR-targeted therapeutics. The discovery of novel GPCRs presented opportunities for developing first-in-class or best-in-class drugs. Therapeutic Areas: The specific therapeutic areas impacted by this patent would depend on the biological functions attributed to the claimed receptors. If these receptors are involved in, for example, oncology, immunology, or neuroscience, then the competitive landscape would include major pharmaceutical companies and biotechnology firms active in those fields. Drug Development Pipeline: The patent would have influenced the drug development pipelines of companies seeking to target these specific receptors. Companies might have: Licensed the technology: Partnered with the patent holder to develop therapeutics. Developed alternative targets: Focused on different receptors or pathways to avoid infringement. Challenged the patent: Attempted to invalidate the patent through litigation if they believed it blocked their development efforts. Market Exclusivity: A valid and enforceable patent grants the holder market exclusivity for the patented invention. For the duration of the patent's life, competitors were generally prevented from making, using, selling, or importing products that infringed the patent claims. This exclusivity allows patent holders to recoup R&D investments and profit from their innovations. Generic Competition: The expiration of the patent on September 28, 2020, opened the door for generic competition. Manufacturers of generic drugs can now produce and sell products that would have infringed the patent, provided they meet regulatory approval requirements and do not infringe other active patents. The ultimate market impact is also contingent on the success of drugs developed based on the patented technology. If therapeutics targeting these receptors proved successful and achieved significant market share, the patent would have been a critical asset for the patent holder and a formidable barrier for competitors. Conversely, if no significant therapeutics emerged from the patent, its market impact would be limited to its influence on R&D strategies and potential licensing revenues. Key Takeaways US Patent 6,569,430 claimed novel receptor polypeptides, their nucleic acids, antibodies, and diagnostic/therapeutic methods. The patent expired on September 28, 2020, meaning its claims are no longer enforceable. The prior art landscape involved well-established GPCR knowledge and receptor discovery techniques, necessitating clear differentiation for patentability. During its term, the patent influenced R&D strategies and market exclusivity for companies developing therapeutics targeting the claimed receptors. The expiration of the patent allows for broader freedom to operate and opens the possibility for generic competition. FAQs Can I use the technology described in US Patent 6,569,430 now that it has expired? Yes, as US Patent 6,569,430 expired on September 28, 2020, the claims are no longer in force. This means the invention is in the public domain, and its use is generally permissible without needing a license from the patent holder. However, it is crucial to ensure that any proposed use does not infringe other valid and active patents. Does the expiration of this patent mean all related drugs are now generic? The expiration of US Patent 6,569,430 means that any products directly covered by its claims can now be manufactured and sold by generic companies. However, a drug may be protected by multiple patents. If a drug developed based on this technology is protected by other active patents (e.g., patents on specific formulations, manufacturing processes, or improved versions), generic entry may still be delayed until those patents expire. What were the primary challenges in examining this patent application? The primary challenges would have involved demonstrating the novelty and non-obviousness of the claimed receptor polypeptides over existing GPCR knowledge and publicly available sequence data. Examiners would have scrutinized whether the claimed sequences and their functions could have been readily predicted or deduced from prior art disclosures. What is the significance of G protein-coupled receptors (GPCRs) as patentable subject matter? GPCRs are critical targets for many therapeutics due to their role in diverse physiological processes. Discoveries of novel GPCRs, their ligands, and related methods of use are highly valuable, making them significant subjects for patent protection. The ability to claim these elements provides a legal framework for recouping substantial R&D investments in this area. Where can I find the specific claims and prosecution history of US Patent 6,569,430? The specific claims, prosecution history, and other related documents for US Patent 6,569,430 can be accessed through the United States Patent and Trademark Office's (USPTO) online databases, such as Public PAIR (Patent Application Information Retrieval) or Patent Center. These resources allow for the retrieval of the patent's file wrapper, which details all interactions between the applicant and the USPTO. Citations [1] United States Patent 6,569,430. (2003, May 27). Receptor polypeptides and methods for their use. The Trustees of the University of Pennsylvania. U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Start Trial	2015-03-21
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Start Trial	2015-03-21
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	⤷ Start Trial	2015-03-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	891069	⤷ Start Trial
World Intellectual Property Organization (WIPO)	8907452	⤷ Start Trial
United States of America	5846534	⤷ Start Trial
New Zealand	227968	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 6,569,430

Summary for Patent: 6,569,430